BAX
BAXTER INTERNATIONAL INC
$20.86
+1.81%
$10.8B
No data for this timeframe.
Vol
Market Cap$10.8B
Cap SizeLarge Cap
Analyst ConsensusSell (4%)
Inst. Holders50 funds
Inst. Value$6.9B
Inst. Activity18 buys / 32 sells
Reddit Sentiment50° Neutral
SEC Reports7
Congressional3 trades
Exchange NYSE·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000010456·Prev Close $20.49
Recent Activity
Jun 12, 2026
short_volume
Short Volume: BAX — 75.4% short (2.0M / 2.6M)
Short: 1,997,141 | Exempt: 1,106 | TRF Vol: 2,649,354 | Short Ratio: 75.4% | Off-exchange volume (da
Jun 12, 2026
Event
IFEX
Currently out of stock.: Estimated recovery in October. (Requirements related to complying with good
Jun 11, 2026
SEC
A mixed institutional cluster in BAX for Q3 2025 shows 7 buyers adding $243.3M in holdings (dominated by Fidelity's doub
INST-CLUSTER — Impact 6/10
Jun 2, 2026
Insider
Wallace Steven P. surrendered for taxes 153 shares
President, Adv. Surgery @ $18.68 ($2.9K)
Jun 2, 2026
Insider
Teaff James surrendered for taxes 321 shares
President, CCS @ $18.68 ($6.0K)
Jun 1, 2026
Insider
Zielinski Anita A was granted 13,426 shares
SVP, Interim CFO, CAO & Cntrlr
May 8, 2026
SEC
Baxter International filed an 8-K adopting a new Executive Severance and Change in Control Plan, amending and restating
8-K — Impact 2/10
Apr 30, 2026
SEC
Baxter reported Q1 2026 adjusted diluted EPS of $0.36, beating the $0.31 consensus by 16.1%, on revenue of $2.70B vs. $2
8-K — Impact 5/10
Price Targets
$21.54
+3.3% upside
Hold
Current $20.86
Low $17.00
Median $19.50
High $40.00
12 analysts
$17.00
$40.00
Analyst Ratings
0Strong Buy
1Buy
16Hold
5Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Citigroup | DOWNGRADE | Neutral → Sell |
| May 4, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| Mar 11, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Feb 17, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.37 | $0.36 — $0.39 | -38% YoY | 11 |
| Next Q | $0.53 | $0.43 — $0.59 | -23% YoY | 11 |
| Current FY | $1.92 | $1.85 — $1.96 | -16% YoY | 13 |
| Next FY | $2.01 | $1.87 — $2.45 | 5% YoY | 14 |
Latest Reports
BEARISH
INST-CLUSTER
6/10
A mixed institutional cluster in BAX for Q3 2025 shows 7 buyers adding $243.3M in holdings (dominated by Fidelity's doub
Jun 11, 2026
NEUTRAL
8-K
2/10
Baxter International filed an 8-K adopting a new Executive Severance and Change in Control Plan, amending and restating
May 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $1.3B | — |
| PZENA INVESTMENT MANAGEMENT LLC | $1.1B | — |
| DODGE & COX | $961.9M | — |
| FMR LLC | $777.2M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $562.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Wallace Steven | F | $2.9K |
| Jun 2, 2026 | Teaff James | F | $6.0K |
| Jun 1, 2026 | Zielinski Anita | A | $0.00 |
| May 5, 2026 | Wilkes David | A | $0.00 |
| May 5, 2026 | Wendell Amy | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
Congressional Trades
1 members: 2 buys, 1 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Michael McCaul | R | BUY | $15,001 - $50,000 |
| Michael McCaul | R | SELL | $100,001 - $250,000 |
| Michael McCaul | R | BUY | $50,001 - $100,000 |
50 institutional holders with $6.9B total value (413,539,237 shares) as of 2026-Q1. Top holders: BlackRock,, PZENA, DODGE. Net selling activity: 32 institutions trimmed/exited vs 18 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 79,400,664 | $1.3B | 19.2% | — |
| 2 | PZENA INVESTMENT MANAGEMENT LLC | 64,527,823 | $1.1B | 15.6% | — |
| 3 | DODGE & COX | 57,254,570 | $961.9M | 13.8% | — |
| 4 | FMR LLC | 46,264,804 | $777.2M | 11.2% | ADD +32.9% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 33,506,975 | $562.9M | 8.1% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 23,993,355 | $403.1M | 5.8% | — |
| 7 | STATE STREET CORP | 19,979,957 | $335.9M | 4.8% | — |
| 8 | Invesco Ltd. | 13,121,171 | $220.4M | 3.2% | — |
| 9 | MORGAN STANLEY | 7,347,972 | $123.4M | 1.8% | — |
| 10 | BANK OF AMERICA CORP /DE/ | 6,166,133 | $103.6M | 1.5% | ADD +44.3% |
| 11 | DIMENSIONAL FUND ADVISORS LP | 5,931,791 | $99.6M | 1.4% | — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5,589,554 | $93.9M | 1.4% | — |
| 13 | Artisan Partners Limited Partnership | 4,861,774 | $81.7M | 1.2% | — |
| 14 | GOLDMAN SACHS GROUP INC | 3,869,555 | $65.0M | 0.9% | — |
| 15 | Russell Investments Group, Ltd. | 3,435,016 | $57.5M | 0.8% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,990,800 | $50.2M | 0.7% | — |
| 17 | VANGUARD FIDUCIARY TRUST CO | 2,896,767 | $48.7M | 0.7% | — |
| 18 | FIL Ltd | 2,589,163 | $43.5M | 0.6% | — |
| 19 | MARSHALL WACE, LLP | 2,266,708 | $38.1M | 0.5% | DOUBLED +8589.4% |
| 20 | DEUTSCHE BANK AG\ | 2,229,998 | $37.5M | 0.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 34,811,770 | 46,264,804 | +32.9% | $777.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 4,273,415 | 6,166,133 | +44.3% | $103.6M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 26,086 | 2,266,708 | +8589.4% | $38.1M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 959,101 | 1,244,312 | +29.7% | $20.9M | 2026-Q1 |
| Legal & General Group Plc | TRIM | 2,434,815 | 968,026 | -60.2% | $16.3M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 620,757 | 913,426 | +47.1% | $15.3M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 409,950 | 906,916 | +121.2% | $15.2M | 2026-Q1 |
| Amundi | TRIM | 1,753,840 | 797,736 | -54.5% | $13.4M | 2026-Q1 |
| Mitsubishi UFJ Asset Management Co., Ltd. | TRIM | 1,113,802 | 621,658 | -44.2% | $10.4M | 2026-Q1 |
| HSBC HOLDINGS PLC | TRIM | 885,280 | 622,865 | -29.6% | $10.4M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 318,581 | 471,447 | +48.0% | $7.9M | 2026-Q1 |
| Gotham Asset Management, LLC | ADD | 181,644 | 361,688 | +99.1% | $6.1M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | DOUBLED | 51,216 | 237,683 | +364.1% | $4.0M | 2026-Q1 |
| GREAT LAKES ADVISORS, LLC | TRIM | 349,836 | 233,388 | -33.3% | $3.9M | 2026-Q1 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | DOUBLED | 67,231 | 146,308 | +117.6% | $2.5M | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 43,385 | 123,652 | +185.0% | $2.1M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 43,090 | 119,913 | +178.3% | $2.0M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 235,375 | 114,227 | -51.5% | $1.9M | 2026-Q1 |
| CIBC Asset Management Inc | NEAR_EXIT | 516,957 | 114,195 | -77.9% | $1.9M | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 158,653 | 100,199 | -36.8% | $1.7M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 151,403 | 89,984 | -40.6% | $1.5M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 253,524 | 83,309 | -67.1% | $1.5M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 171,565 | 85,524 | -50.2% | $1.4M | 2026-Q1 |
| ALLSTATE CORP | DOUBLED | 37,162 | 84,793 | +128.2% | $1.4M | 2026-Q1 |
| Cerity Partners LLC | TRIM | 113,866 | 59,042 | -48.1% | $991.9K | 2026-Q1 |
16 unique insiders with 37 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Wallace Steven P. | President, Adv. Surgery | TAX W/H | 153 | $18.68 | $2.9K |
| Jun 2, 2026 | Teaff James | President, CCS | TAX W/H | 321 | $18.68 | $6.0K |
| Jun 1, 2026 | Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | AWARD | 13,426 | — | — |
| May 5, 2026 | Wilkes David S. | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | Wendell Amy McBride | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | SCHLICHTING NANCY M | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | MORRISON PATRICIA | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | Shafer David Brent | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | Craig Jeffrey A | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | Ampofo William A. II | Director | AWARD | 12,836 | — | — |
| Mar 6, 2026 | Grade Joel T. | EVP and CFO | TAX W/H | 8,153 | $17.69 | $144.2K |
| Mar 6, 2026 | Rasul Reazur | EVP,Group Pres,Healthcare | TAX W/H | 12,674 | $17.69 | $224.2K |
| Mar 6, 2026 | Rosenbloom David S. | EVP and General Counsel | TAX W/H | 6,620 | $17.69 | $117.1K |
| Mar 6, 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | TAX W/H | 2,848 | $17.69 | $50.4K |
| Mar 6, 2026 | Zielinski Anita A | SVP, CAO and Controller | TAX W/H | 1,932 | $17.69 | $34.2K |
| Mar 2, 2026 | Rasul Reazur | EVP,Group Pres,Healthcare | TAX W/H | 1,614 | $19.69 | $31.8K |
| Mar 2, 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | TAX W/H | 1,852 | $19.69 | $36.5K |
| Mar 2, 2026 | Rosenbloom David S. | EVP and General Counsel | TAX W/H | 1,336 | $19.69 | $26.3K |
| Feb 27, 2026 | Carlisle Cynthia | Executive Vice President, CHRO | AWARD | 43,103 | — | — |
| Feb 27, 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | AWARD | 23,742 | — | — |
| Feb 27, 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | AWARD | 57,471 | — | — |
| Feb 27, 2026 | Rosenbloom David S. | EVP and General Counsel | AWARD | 64,655 | — | — |
| Feb 27, 2026 | Grade Joel T. | EVP and CFO | AWARD | 103,448 | — | — |
| Feb 27, 2026 | Hider Andrew P. | President and CEO | AWARD | 201,804 | — | — |
| Feb 27, 2026 | Hider Andrew P. | President and CEO | AWARD | 488,506 | — | — |
| Feb 27, 2026 | Zielinski Anita A | SVP, CAO and Controller | AWARD | 30,864 | — | — |
| Feb 27, 2026 | Carlisle Cynthia | Executive Vice President, CHRO | AWARD | 17,806 | — | — |
| Feb 27, 2026 | Rosenbloom David S. | EVP and General Counsel | AWARD | 26,709 | — | — |
| Feb 27, 2026 | Grade Joel T. | EVP and CFO | AWARD | 42,735 | — | — |
| Feb 9, 2026 | Grade Joel T. | EVP and CFO | AWARD | 30,504 | — | — |
| Feb 9, 2026 | Grade Joel T. | EVP and CFO | TAX W/H | 9,144 | $21.73 | $198.7K |
| Feb 9, 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | AWARD | 2,273 | — | — |
| Feb 9, 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | TAX W/H | 918 | $21.73 | $19.9K |
| Feb 9, 2026 | Rosenbloom David S. | EVP and General Counsel | AWARD | 17,055 | — | — |
| Feb 9, 2026 | Rosenbloom David S. | EVP and General Counsel | TAX W/H | 5,225 | $21.73 | $113.5K |
| Feb 9, 2026 | Rasul Reazur | EVP,Group Pres,Healthcare | AWARD | 18,951 | — | — |
| Feb 9, 2026 | Rasul Reazur | EVP,Group Pres,Healthcare | TAX W/H | 5,770 | $21.73 | $125.4K |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 4.1/10.
BEARISH
INST-CLUSTER
6/10
A mixed institutional cluster in BAX for Q3 2025 shows 7 buyers adding $243.3M in holdings (dominate
Jun 11, 2026
NEUTRAL
8-K
2/10
Baxter International filed an 8-K adopting a new Executive Severance and Change in Control Plan, ame
May 8, 2026
MIXED
8-K
5/10
Baxter reported Q1 2026 adjusted diluted EPS of $0.36, beating the $0.31 consensus by 16.1%, on reve
Apr 30, 2026
NEUTRAL
DEFA14A
2/10
Baxter International filed additional definitive proxy materials (DEFA14A) urging stockholders to vo
Apr 29, 2026
NEUTRAL
COURT-RULING
5/10
{
"summary": "The Appellate Division of the New York Supreme Court reversed a lower court decision
Mar 27, 2026
NEUTRAL
DEFA14A
2/10
Baxter International Inc. filed a definitive proxy statement (DEFA14A) related to a shareholder vote
Mar 23, 2026
BULLISH
INST-CLUSTER
7/10
Three major institutional investors—Fidelity, Morgan Stanley, and Norges Bank—significantly increase
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Sell (4% buy). Based on 24 analysts: 0 strong buy, 1 buy, 16 hold, 5 sell, 2 strong sell.
Analyst Price Targets
$21.54 mean target
+3.3% upside
Hold (2.86)
$17.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $20.86 |
| Target Low | $17.00 |
| Target Mean | $21.54 |
| Target Median | $19.50 |
| Target High | $40.00 |
| # Analysts | 12 |
| Recommendation | Hold (2.86) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.37 | $0.36 | $0.39 | -37.6% | +0.0% | 0↑ 12↓ | $2.8B | -0.4% | 11 |
| Next Q 2026-09-30 |
$0.53 | $0.43 | $0.59 | -22.9% | +0.0% | 5↑ 7↓ | $2.9B | 0.8% | 11 |
| Current FY 2026-12-31 |
$1.92 | $1.85 | $1.96 | -15.6% | -0.0% | 6↑ 2↓ | $11.4B | 1.0% | 13 |
| Next FY 2027-12-31 |
$2.01 | $1.87 | $2.45 | 5.0% | +0.1% | 7↑ 7↓ | $11.6B | 2.0% | 14 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.368 | |
| 7d ago | $0.368 | |
| 30d ago | $0.368 | |
| 60d ago | $0.440 | -0.072 |
| 90d ago | $0.435 | -0.067 |
4 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Citigroup | DOWNGRADE | Neutral | Sell |
| May 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Mar 11, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 17, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 13, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 9, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 1 | 16 | 5 | 2 | 4% | |
| May 1, 2026 | 1 | 4 | 16 | 1 | 0 | 23% | |
| Apr 1, 2026 | 1 | 4 | 16 | 1 | 0 | 23% | |
| Mar 1, 2026 | 1 | 4 | 16 | 1 | 0 | 23% | |
| Feb 1, 2026 | 0 | 2 | 16 | 6 | 1 | 8% | |
| Jan 1, 2026 | 0 | 2 | 16 | 6 | 1 | 8% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 2 buys, 1 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | Michael McCaul | R | HOUSE | BUY | $15,001 - $50,000 | Baxter International Inc | Apr 10, 2026 (19d) |
| Feb 17, 2026 | Michael McCaul | R | HOUSE | SELL | $100,001 - $250,000 | Baxter International Inc | Mar 12, 2026 (24d) |
| Jan 13, 2026 | Michael McCaul | R | HOUSE | BUY | $50,001 - $100,000 | Baxter International Inc | Feb 12, 2026 (31d) |
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 10, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 12, 2026
short_volume
Short Volume: BAX — 75.4% short (2.0M / 2.6M)
Short: 1,997,141 | Exempt: 1,106 | TRF Vol: 2,649,354 | Short Ratio: 75.4% | Off-exchange volume (dark pool + OTC)
Jun 12, 2026
FDA
IFEX
Currently out of stock.: Estimated recovery in October. (Requirements related to complying with good manufacturing practices) [Oncology, Pediatric]
Jun 11, 2026
short_volume
Short Volume: BAX — 66.4% short (1.6M / 2.5M)
Short: 1,645,386 | Exempt: 92 | TRF Vol: 2,479,571 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: BAX — 67.5% short (2.6M / 3.9M)
Short: 2,618,249 | Exempt: 18,520 | TRF Vol: 3,881,498 | Short Ratio: 67.5% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: BAX — 63.8% short (1.1M / 1.8M)
Short: 1,134,023 | Exempt: 403 | TRF Vol: 1,777,731 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: BAX — 62.3% short (1.3M / 2.2M)
Short: 1,349,159 | Exempt: 0 | TRF Vol: 2,166,000 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: BAX — 75.3% short (1.7M / 2.3M)
Short: 1,725,502 | Exempt: 1,143 | TRF Vol: 2,292,512 | Short Ratio: 75.3% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: BAX — 78.5% short (1.3M / 1.6M)
Short: 1,278,712 | Exempt: 593 | TRF Vol: 1,628,945 | Short Ratio: 78.5% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: BAX — 69.9% short (1.6M / 2.3M)
Short: 1,624,538 | Exempt: 1,608 | TRF Vol: 2,324,853 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
FDA
TRAVASOL
Unavailable: Estimated recovery: TBD (Shortage of an inactive ingredient component) [Gastroenterology]
Jun 2, 2026
FDA
CLINDAMYCIN PHOSPHATE
Limited Availability: Estimated recovery: July 2026 (Other) [Anti-Infective]
Jun 2, 2026
FDA
DEXTROSE
Limited Availability: Estimated recovery: June 2026 (Other) [Endocrinology/Metabolism, Gastroenterology, Other, Pediatric]
Jun 1, 2026
short_volume
Short Volume: BAX — 60.7% short (1.7M / 2.8M)
Short: 1,707,487 | Exempt: 1,362 | TRF Vol: 2,813,576 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: BAX — 72.2% short (1.1M / 1.6M)
Short: 1,134,062 | Exempt: 34 | TRF Vol: 1,571,660 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: BAX — 71.6% short (1.3M / 1.9M)
Short: 1,326,997 | Exempt: 2,948 | TRF Vol: 1,854,342 | Short Ratio: 71.6% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: BAX — 80.4% short (2.4M / 2.9M)
Short: 2,365,132 | Exempt: 2,063 | TRF Vol: 2,942,151 | Short Ratio: 80.4% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: BAX — 69.8% short (1.2M / 1.8M)
Short: 1,223,247 | Exempt: 5,271 | TRF Vol: 1,752,184 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Phase Phase 3 — COMPLETED
May 22, 2026
short_volume
Short Volume: BAX — 59.4% short (1.7M / 2.9M)
Short: 1,741,027 | Exempt: 320 | TRF Vol: 2,929,105 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: BAX — 72.2% short (2.1M / 2.9M)
Short: 2,085,554 | Exempt: 2,642 | TRF Vol: 2,886,783 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
May 17, 2026
Clinical Trial
Krill Oil for Pain in Elders
Phase Phase 2 — COMPLETED
May 16, 2026
FDA
HEPARIN SODIUM IN SODIUM CHLORIDE
Unavailable: Estimated recovery: July 2026 (Demand increase for the drug) [Hematology]
Mar 16, 2026
Clinical Trial
Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
Phase Phase 2 — COMPLETED
Mar 16, 2026
Clinical Trial
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Phase Phase 3 — COMPLETED
Mar 12, 2026
Clinical Trial
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Phase Phase 2 — COMPLETED